

Effect of Angiotensin Converting Enzyme Inhibitor on Collagen Production by Cultured Mesangial Cells

Chun-Gyoo Ihm, M.D., Jae-Kyung Park, M.D., Jae-Hyung Ahn, M.D.,
Tae-Won Lee, M.D. and Myung-Jae Kim, M.D.

Department of Internal Medicine, Kyunghee University College of Medicine, Seoul, Korea

Cultured mesangial cells (MC) express renin mRNA and generate angiotensin I, supporting the action of local renin-angiotensin system. Also angiotensin II may act like a growth factor and was reported to increase collagen production (CP) in cultured MC. Angiotensin converting enzyme inhibitor is suggested to attenuate development and advancement of glomerulosclerosis, mainly with its hemodynamic effects. Therefore, we investigated the direct effects of enalapril (E) on CP by cultured MC. Rat MC were cultured in DMEM media alone, or containing high glucose (HG: 25 mM) or soluble immune complex (IC) prepared with bovine gamma globulin (BGG) and anti-BGG, with or without E (0.2 ug/ml). CP was determined after 24 h by [³H] proline incorporation method. E significantly reduced CP by 43% in medium as compared with control (C) (C: 37,210±4,200 vs C+E: 21,350±5,080 cpm/well, *p*<0.01). CP in medium increased in the presence of HG (123% of C) or IC (147% of C), which was, however, prevented with E (HG+E: 105% of C, IC+E: 116% of C). There were no differences of CP in cell layer between C (3,490±220 cpm/well) and C+E (3,340±190 cpm/well), and also no changes after addition of E in HG or IC groups. In conclusion, E directly attenuates CP by MC, even in the presence of HG or IC, independently of its hemodynamic effects.

Key Words: Enalapril, Collagen production, Mesangial cell, Immune complex, High glucose

INTRODUCTION

It's recently been suggested that the glomerular mesangial expansion may be the common pathway into the development of glomerulosclerosis in several glomerular diseases, such as immune-mediated glomerulonephritis and diabetic nephropathy^{1,2}. It's reported to be due to the synthesis and accumulation of extracellular matrix proteins (ECM) such as collagen³⁻⁹.

Since the methods of mesangial cell culture were established¹⁰, the mesangial cells (MC) have been observed to proliferate or produce ECM in response to injurious stimuli^{2,3,10} and also to secrete biologically active substances such as cytokine growth factors as effector cells¹¹⁻¹⁶. Especially, it's interesting to determine whether high glucose or immune complex (IC) could exert any

effects on MC^{8,17-20}.

MC were reported to express renin-like enzyme activity and generate angiotensin^{21,22}. Angiotensin II was observed to increase collagen production in cultured MC²³ and, therefore, may act as a growth factor. Also, angiotensin converting enzyme (ACE) inhibitor has been suggested to attenuate glomerulosclerosis, probably mainly through its hemodynamic effect²⁴⁻²⁷, which remain controversial with recent studies²⁸⁻³⁰.

Therefore, the direct effect of ACE inhibitor, enalapril, on MC were investigated from the aspects of collagen production or DNA synthesis. Also, it was examined whether soluble IC or high glucose exert any effects on cultured MC, and these changes are modulated by enalapril in vitro.

METHODS

Isolation and identification of rat glomerular MC: Glomeruli were isolated from Sprague-Dawley rats using techniques previously described^{10,14}. Collagenase (GIBCO Laboratories, Grand Island, NY, USA)-treated glomeruli were plated on culture dishes in DMEM media containing 17% heat-

Address reprint requests to: Chun-Gyoo Ihm, M.D.,
Division of Nephrology, Department of Internal
Medicine, Kyunghee University Medical Center, #1
Hoiki-Dong, Dongdaemum-Ku, Seoul, 130-702,
Korea, Phone (02) 966-5191 (ext. 2319). FAX (02)
968-1848

inactivated fetal bovine serum (FBS), glutamine, penicillin, streptomycin, amphotericin and insulin. Near confluent cells in third to fourth passage were used in these studies. The cells have prominent intracellular myosin fibrils and were negative with antibodies (Becton Dickinson, Mountain View, CA, USA) to common leukocyte antigen and factor VIII by immunofluorescent staining. The cells were capable of growth in D-valine substituted medium and were not sensitive to puromycin.

Experimental groups: the medium was replaced according to the experimental design shown as follows. 1) Control, 2) Enalapril group; enalapril 0.2 $\mu\text{g/ml}$, 3) IC prepared with bovine γ -globulin (BGG) and rabbit IgG anti-BGG at five times excess antigen as previously described¹⁷⁾, 4) IC+enalapril group, 5) High glucose; 25 mM glucose, 6) High glucose+enalapril group.

Collagen and non-collagen protein production: De novo collagen synthesis was measured by the incorporation of [³H] proline into collagenase-digestible material as described³¹⁾. MC were plated at 1×10^5 cells per well in 6-well plates in basal medium supplemented with 17% FBS and 5.6 mM (100 mg/dl) glucose. After 72 hr of starvation with serum-free medium, the medium was again changed to medium with 0.2% FBS, 5.6 mM (100 mg/dl) glucose, 50 μg each of sodium ascorbate and β -aminopropionitrile, and the indicated amount of various materials according to the experimental design as mentioned above. The cells were labeled with 5 μCi of [³H] proline (Amersham Corp., Arlington Heights, IL, USA). After 24 hr incubation, the proteins in cell and medium were precipitated with 2 ml of 10% TCA and 1% tannic acid. The washed precipitates were dissolved in 0.1 N NaOH and neutralized, and the solubilized proteins were digested with 100 units of highly purified collagenase (GIBCO) in 0.1 M Tris-buffer (pH=7.6) containing 10 mM CaCl₂ and 20 mM N-ethyl maleimide for 1 hr at 37°C. Collagenase digestible protein and non-collagenous protein were separated with TCA and tannic acid and the radioactivity of each fraction was determined.

Thymidine incorporation assays: Cells were plated at 1×10^4 cells per well 96-well plates in DMEM medium containing 17% FBS. One μCi per well of [³H] thymidine (New England Nuclear, Boston, Massachusetts, USA) was added after the medium was replaced according to the experimental design. After 16 hr incubation, the contents of each well were counted in a liquid scintillation counter³²⁾.

Statistical Analysis

The results are expressed as mean \pm SEM. Statistical evaluation of the data was performed using a Student's t test and ANOVA. Probability values < 0.05 were considered significant.

RESULTS

Collagen production in medium by MC in Enalapril group was significantly lower than Control for the first 24 hours and was 57% of control (Enalapril group: $21,350 \pm 5,080$ vs Control: $37,210 \pm 4,200$ cpm/well, $n=6$, $p < 0.01$) (Table 1, Fig. 1). No differences of non-collagen production in medium were noticed between the two groups. Therefore, the ratio to collagen/total protein production was lower in Enalapril group than in Control. However, there were no differences of collagen production in cell layer between Control ($3,490 \pm 220$ cpm/well)

Table 1. Effects of Enalapril on Collagen Production by Mesangial Cells

	(cpm/well, mean \pm SD)	
	Medium	Cell layer
Control (n=6)	$37,210 \pm 4,200$	$3,490 \pm 220$
Enalapril (n=6)	$21,350 \pm 5,080^*$	$3,340 \pm 190$

* $p < 0.01$ vs Control




Fig. 1. Collagen production in medium by mesangial cells (Mean \pm SD) was significantly reduced by enalapril (* $p < 0.01$ vs control).

and Enalapril group (3,340±190 cpm/well).

Collagen production in medium was significantly higher in the presence of IC or High glucose (147% and 123% of Control, respectively) than in Control (p<0.05)(Fig. 2). But, IC or high glucose-induced increases in collagen production were significantly prevented with the addition of enalapril (116% and 105% of Control, respectively, p<0.05).

When cultured in soluble IC or high glucose, the thymidine incorporation of mesangial cells was decreased as compared with control (63.5% and 72.6% of control, respectively, p<0.05)(Table 3). The addition of enalapril, however, exerted no effects on these changes in IC or High glucose groups.

DISCUSSION

According to these experiments, ACE inhibitor, enalapril, could directly reduce collagen production by MC in vitro. This supports the recent studies that ACE inhibitor could prevent the progression of renal disease in the absence of hemodynamic effects. Also, it suggests that there is the local renin-angiotensin system in cultured MC which enalapril could inhibit.

It has been demonstrated that angiotensin II as a growth factor can induce cellular hypertrophy and also proliferation in MC^{23,33-35}. Angiotensin II directly stimulates the synthesis of extracellular matrix proteins, mainly type I collagen²³. Also angiotensin II was observed to induce the synthesis of interleukin-6³⁶ and platelet activating factor³⁷ in MC, offering multiple possibilities for the regulation of autocrine and/or paracrine effects of this peptide. Therefore, it's also possible that the effects of angiotensin II to stimulate collagen production may, in part at least, be mediated by these growth factors. Recently, AT1-angiotensin II receptor was observed to be expressed in MC of human and animals^{38,39}. Current evidences suggest that the AT1 receptor is coupled via G proteins to traditional signal transduction mechanisms such as stimulation of phospholipase C, calcium mobilization and inhibition of adenylate cyclase⁴⁰.

On the other hand, high glucose induced increases in collagen production by MC in these experiments, as previously reported^{19,20}. High glucose may activate the polyol pathway increasing the glycosylation of proteins by nonenzymatic means, or stimulate second messenger pathways resulting in alterations in the synthesis or degradation of extracellular matrix proteins⁴¹. Also, IC stimulated collagen production by MC in these experiments. Soluble IC was previously observed to bind to cultured MC through Fc receptor and to activate MC¹⁷. While high glucose was related to transforming growth factor-β⁴², IC were also re-




Fig. 2. The immune complex or high glucose-induced increases in collagen production in medium were prevented by enalapril (% of mean control value). C: control, IC: immune complex, HG: high glucose, E: enalapril. *p<0.05 IC vs C or IC+E, HG vs C or HG+E **p<0.05 IC+E vs C

Table 2. Effect of Enalapril on Non-Collagen Production Mesangial Cells

	(cpm/well, Mean ± SD)	
	Medium	Cell layer
Control (n=6)	21,430±2,430	2,780±210
Enalapril (n=6)	24,140±3,200	2,590±300

Table 3. Effects of Enalapril on Thymidine Incorporation Induced by Immune Complex or High Glucose

	Thymidine incorporation (% of Control)	
	Without Enalapril	With Enalapril
Immune complex (n=6)	63.5 ± 4.0	68.0 ± 7.9
High glucose (n=6)	72.6 ± 15.4	70.0 ± 17.2

all are decreased as compared with control (p<0.05)

ported to stimulate the synthesis of interleukin-1 and -6^{18,43}. All of these factors could induce the synthesis of extracellular matrix proteins^{44,45}. Therefore, our study complements the reports that collagen synthesis and accumulation leading to mesangial expansion and/or late glomerulosclerosis was increased in IC-mediated glomerulonephritis or diabetic nephropathy models^{4,5,9,46}. According to these experiments, enalapril can reduce the increase in collagen production induced by IC and high glucose. While the underlying mechanisms remain to be delineated, it may be through the inhibition of generation of angiotensin II and related to the above pathways or interaction with growth factors.

When cultured in soluble IC or high glucose in these experiments, the thymidine uptake by MC was decreased, and the addition of enalapril, however, exerted no effects on these changes. The proliferative effects of angiotensin II have not been confirmed by all investigators³³.

In conclusion, ACE inhibitor, enalapril, could directly reduce collagen production by MC, also induced by IC or high glucose, irrespective of its hemodynamic effects. Further studies are necessary to investigate the intracellular mechanisms on the levels of collagen gene expression and the interaction of some autocrine growth factors by using this culture model.

ACKNOWLEDGMENT

This study was supported by the Chong-Ram grant in 1990 from the Korean Association of Internal Medicine

REFERENCES

- Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC: *Structural functional relationships in diabetic nephropathy*. *J Clin Invest* 74:1143, 1984
- Klahr S, Schreiner G, Ichikawa I: *The progression of renal disease*. *N Engl J Med* 318:1657, 1988
- Ayo SH, Rodnik RA, Garoni J, Glass II WF, Kreiberg JI: *High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells*. *Am J Pathol* 136:1339, 1990
- Falk RJ, Scheinman JI, Mauer SM, Michael AF: *Polyantigenic expansion of basement membrane constituents in diabetic nephropathy*. *Diabetes* 32(Suppl 2):34, 1983
- Floege J, Hohnson RJ, Gordon K, Iida H, Pritzl P, Yoshimura A, Campbell, Alpers CE and Couser WG: *Increased synthesis of extracellular matrix in mesangial proliferative nephritis*. *Kidney Int* 40: 477, 1991
- Okuda S, Languino LR, Ruoslahti E, Border WA: *Elevated expression of transforming growth factor- β and proteoglycan production in experimental glomerulonephritis*. *J Clin Invest* 86:453, 1990
- Goyal M, Wiggins R: *Fibronectin mRNA and protein accumulation, distribution, and breakdown in rabbit anti-glomerular basement membrane disease*. *J Am Soc Nephrol* 1:1334, 1991
- Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H: *Effects of methylprednisolone on glomerular and medullary mRNA levels for extracellular matrices in puromycin aminonucleoside nephrosis*. *Kidney Int* 40:874, 1991
- Striker LM, Killen PD, Chi E, Striker GE: *The composition of glomerulosclerosis. I. studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis*. *Lab Invest* 51:181, 1984
- Striker GE, Striker LJ: *Glomerular cell culture*. *Lab Invest* 53:122, 1985
- Shultz PA, Dicorleto PE, Silver BJ, Abboud HE: *Mesangial cells express PDGF mRNAs and proliferate in response to PDGF*. *Am J Physiol* 255: F674, 1988
- Joza C, Benigni A, Renzi D, Piccinelli A, Perico N, Remuzzi G: *Endothelin and eicosanoid synthesis in cultured mesangial cells*. *Kidney Int* 37:927, 1990
- Ruef C, Budde K, Lacy J, Northemann W, Baumann M, Sterzel RB, Coleman DL: *Interleukin 6 is an autocrine factor for mesangial cells*. *Kidney Int* 38:249, 1990
- Lovett DH, Szamel M, Ryan JL, Sterzel RB, Gemsa D, Resch K: *Interleukin 1 and the glomerular mesangium; I. Purification and characterization of a mesangial cell-derived autogrowth factor*. *J Immunol* 136:3700, 1986
- Conti GF, Striker LJ, Elliot SJ, Andreani D, Striker GE: *Synthesis and release of insulinlike growth factor I by mesangial cells in culture*. *Am J Physiol* 255:F1214, 1988
- Werber HI, Emancipator SN, Tykocinski ML, Sedor JR: *The IL-1 gene is expressed by rat glomerular mesangial cells and is augmented in immune complex glomerulonephritis*. *J Immunol* 138:3107, 1987
- Sedor JR, Carey SW, Emancipator SN: *Immune complexes bind to cultured rat glomerular mesangial cells to stimulate superoxide release*. *J Immunol* 138:3751, 1987
- Matsumoto K, Hatano M: *Soluble immune com-*

- plexes stimulate production of interleukin-1 by cultured rat glomerular mesangial cells. *Am J Nephrol* 11:138, 1991
19. Bernstein J, Cheng F, Roszka J: Increased glucose increases glomerular basement membrane in metanephric culture. *Pediatr Nephrol* 1: 3, 1987
 20. Ihm CG, Park JK, Ahn JH, Lee TW, Kim MJ: Effects of glucose, insulin and somatostatin on collagen production by glomerular mesangial cells. *Korean J of Nephrol* 11:200, 1992
 21. Chansel D, Dussaule J-C, Ardillou N, Ardillou R: Identification and regulation of renin in human cultured mesangial cells. *Am J Physiol* 252:F32, 1987
 22. Dzau VJ, Kreisberg JI: Cultured glomerular mesangial cells contain renin: influence of calcium and isoproterenol. *J Cardiovasc Pharmacol* 8(Suppl. 1):S6, 1986
 23. Wolf G, Haberstroh U, Heilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. *Am J Pathol* 140:95, 1992
 24. Navar IG, Rosivall L: Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics. *Kidney Int* 25:857, 1984
 25. Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM: Role of angiotensin II in the altered renal function of congestive heart failure. *Circ Res* 55:669, 1984
 26. Pelayo JC, Quan Ah, Shanley PF: Angiotensin II control of the renal microcirculation in rats with reduced renal mass. *Am J Physiol* 258:F414, 1990
 27. Kastner PR, Hall JE, Guyton AC: Control of glomerular filtration rate: Role of intrarenally formed angiotensin II. *Am J Physiol* 246:F414, 1990
 28. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. *J Clin Invest* 77:1993, 1986
 29. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I: Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesion. *Kidney Int* 40:195, 1991
 30. Wight JP, Bassett AH, Le Carpentier JE, E1 Nahas AM: Effect of treatment with enalapril, verapamil and indomethacin on compensatory renal growth in the rat. *Nephrol Dial Transplant* 5:777, 1990
 31. Hakeda Y, Nakatani Y, Kurihara N, Ikeda E, Maeda N, Kumegawa M: Prostaglandin E2 stimulates collagen and non-collagen protein synthesis and prolyl hydroxylase activity in osteoblastic clone MC3T3-E1 cells. *Biochem Biophys Res Comm* 126:340, 1985
 32. MacKay K, Striker LJ, Stauffer JW, Doi T, Agodoa LY, Striker GE: Transforming growth factor- β *J Clin Invest* 83:1160, 1989
 33. Homma T, Hoover RL, Ichikawa I, Harris RC: Angiotensin II induces hypertrophy and stimulates collagen production in cultured rat glomerular mesangial cells [Abstract]. *Clin Res* 38:358, 1990
 34. Anderson PW, Do YS, Hsueh WA: Angiotensin II causes mesangial cell hypertrophy (Abstract). *Hypertension* 18:382, 1991
 35. Ray PE, Aguilera G, Kopp JB, Horikoshi S, Klotman PE: Angiotensin II receptor-mediated proliferation of cultured human fetal mesangial cells. *Kidney Int* 40:764, 1991
 36. Fujibayashi M, Fujiwara Y, Fukunaga M: Vasoconstrictors stimulate interleukin 6 (IL-6) release from mouse mesangial cells (Abstract). *J Am Soc Nephrol* 2:437, 1991
 37. Neuwirth R, Satriano JA, DeCandido S, Clay K, Schlondorff D: Angiotensin II causes formation of platelet activating factor in cultured rat mesangial cells. *Cir Res* 1224, 1989
 38. Groene JH, Simon M, Fuchs E: Autoradiographic characterization of angiotensin receptor subtypes in fetal and adult human kidney. *Am J Physiol* 262:F326, 1992
 39. Sechi LA, Grady EF, Griffin CA, Kalinyak JE, Schambelan M: Distribution of angiotensin II receptor subtypes in rat and human kidney. *Am J Physiol* 262:F236, 1992
 40. Wolf G, Neilson EG: Angiotensin II as a renal growth factor. *J Am Soc Nephrol* 3:1531-1540, 1993
 41. Kreisberg JI: Biology of disease. Hyperglycemia and microangiopathy. Direct regulation by glucose of microvascular cells. *Lab Invest* 67:416, 1992
 42. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN: High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF- β . *Kidney Int* 42:647, 1992
 43. Dobbelsteen MEa, Woude FJ, Schroeijers WEM, Es LA, Daha MR: Soluble aggregates of IgG and immune complexes enhance IL-6 production by renal mesangial cells. *Kidney Int* 43:544, 1993
 44. Border WA, Okuda S, Languino LR, Ruslahti E: Transforming growth factor- β regulates production of proteoglycans by mesangial cells. *Kidney Int* 37:689, 1990
 45. Torbohm I, Berger B, Schoenermark M, Kempis JV, Rother K, Haensch GM: Modulation of collagen synthesis in human glomerular epithelial cells by interleukin-1. *Clin Exp Immunol* 75:427, 1989
 46. Ihm CG, Lee GSL, Nast CC, Artishevsky A, Guillermo R, Levin PS, Glasscock RJ, Adler SG: Early increased renal procollagen $\alpha 1(IV)$ mRNA levels in streptozotocin induced diabetes. *Kidney Int* 41:768, 1992